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ABSTRACT 
Introduction: Age-related macular degeneration (AMD) is a neurodegenerative disease which 
is one of the leading causes of vision loss affecting population above the age of 50 years. Of the 
two types wet and dry AMD, dry AMD constitute 90% of cases. Currently there is no effective 
treatment for AMD except for antioxidant supplementation which can delay the progression 
of AMD and its associated vision loss. In Ayurveda, it is a Vata Pitthadhika Drishtigata Roga 
compounded by Dhatukshaya in Vardhakya. The treatment should be Brimhana, Chakshushya 
and Rasayana to tackle the degenerative changes. Gandhaka Kalpa from Rasaratnasamucchaya 
and Ksheerabala 101 Avarti Taila has these properties to ameliorate the disease pathology. 
Hence a clinical study was planned with the objective to assess the effect of Gandhakakalpa 
internally and Ksheerabala 101 Avarti Taila Nasya in dry AMD. 
Methods: The study design was interventional, pre and post evaluation without control. After 
preparatory phase, patients were given Nasya with Ksheerabala 101 Avarti Taila followed by 
administration of Gandhaka Kalpa with concurrent administration of Ksheerabala 101 Avarti 
Taila as Pratimarsa Nasya. Study and follow up were done in 30 eyes. Results were documented 
and statistically analysed using Friedmains’s test, paired t test, Wilcoxon’s signed rank test and 
McNemar test according to type of variable. 
Result: The intervention is statistically significant while considering visual acuity (p < 0.001) 
and Daily Living Tasks Dependent on Vision questionnaire scores (p< 0.0001) and not 
significant for optical coherence tomography and Amsler grid findings. 
Conclusion: The intervention is an effective protocol to be followed in Ayurveda for dry AMD. 
KEYWORDS: Dry AMD, Gandhaka Kalpa, Ksheerabala 101 Avarti Taila, Nasya. 
INTRODUCTION 
The elderly population, which forms a 
significant part of the demography, is unique in the 
sense that they have a set of health problems that are 
found exclusively in that population. As the age 
progresses, the sense organs start to deteriorate, thus 
affecting the quality of life and daily routine of 
already struggling individuals. Age related macular 
degeneration (AMD) is such a disease affecting 
individuals above the age of 50 years. Its prevalence 
increases with age and is one of the leading causes of 
blindness in elderly population globally. Dry form of 
AMD forms 90% of affected cases. Kulkarni et. al 
reported the overall proportion of AMD in 
Maharashtra was 1.38%.[1]  The estimated statistics of 
people with age-related macular degeneration in 
2020 is 196 million, increasing to 288 million in 
2040.[2] Hence it is an important public health issue. 
For such a disease burden, currently there is no 
effective treatment except for antioxidant 
supplementation to reduce the risk of advanced AMD 
and its associated vision loss. In Ayurveda, it is 
considered a Drishtigataroga. Vardhakyaavastha of 
age produces indriya and Dhatudourbalyata. The 
symptoms of AMD are found in various Drishtigata 
rogas. But it is not possible to limit its clinical 
presentation to any one of the classically described 
Drishtirogas. It appears to have a Vata -pitta dosha 
predominance with associated Raktavahasrotodushti. 
Here the treatment should be Chakshushya, rasayana 
and Brimhana to tackle the degenerative changes. 
Gandhakakalpa, the reference of which is found in 
Rasasatnasamuchaya Uparasa niroopanaadhyaya, is 
said to bring eye sight as sharp as that of a hawk on 
internal administration.[3] The Kalpa selected here 
has Gandhaka, Bhringaraja Swarasa, Triphala 
choorna as ingredients. Nasya is a Panchakarma 
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procedure indicated especially in diseases affecting 
head. Ksheerabala Taila which is Rasayana, 
Jeeevaneeya, Brimhaneeya and Indriyaprasadana[4] is 
taken for Nasya as this is a degenerative disease due 
to Dhatukshaya in body as a result of Vardhakya 
affecting Darsanendriya. In Ayurveda, dry AMD is a 
relatively unexplored avenue for research. Given the 
neurodegenerative nature of AMD and the lack of a 
standard effective management in other systems of 
health care, this area warrants active research. The 
drugs chosen for the study are safe, inexpensive and 
have potent antioxidant properties. Hence this study 
was undertaken as a lacuna was felt in the research 
related to this disease.  
Aim 
To study the effect of Gandhaka Kalpa 
internally and Ksheerabala 101 Avarti Taila Nasya in 
Dry Age -related Macular Degeneration. 
MATERIALS AND METHODS 
Study design 
Pre and post Interventional trial without control. 
Study setting 
Department of Shalakyathantra, Govt: Ayurveda 
College, Trivandrum. 
Selection of patients 
Patients diagnosed as dry age related macular 
degeneration (dry AMD) from OPD and IPD of 
Shalakyathantra, Government Ayurveda College, 
Trivandrum, fulfilling exclusion and inclusion 
criteria, 30 eyes in total were selected by consecutive 
sampling. Study was completed in 24 eyes. 
Exclusion criteria 
1. Uncontrolled hypertension or diabetes 
2. Patients with mature cataract, high myopia, 
glaucoma, other retinal degenerations 
3. Patients with systemic illness like uncontrolled 
hypercholestremia, liver disease, renal disease 
4. Pigment epithelium detachment 
5. Nasya Anarha 
Study tool: 
a. Case proforma 
b. Modified Daily Living Tasks Dependent on Vision 
questionnaire (DLTV) questionnaire specific to 
Macular degeneration  
c. Investigations 
 LogMar Chart 
 Amsler grid 
 Ophthalmoscopy 
 OCT 
Clinical evaluation and investigations was done 
prior to the commencement of interventions, after 
treatment and 2 months after treatment. 
Study drugs 
Gandhakakalpa and Ksheerabala 101 Avarti Taila. 
Ksheerabala Taila was prepared according to 
standard procedure mentioned in AFI.[5] For 
preparing Gandhaka Kalpa, Gandhaka was first 
purified by Kurmaputa method and later triturated 
with Bhringarajaswarasa. Gandhaka Kalpa was then 
dispensed in 3g packages by mixing 750mg of 
purified Gandhaka with 2.25gm of Triphalachoorna. 
Procedure 
After obtaining informed consent, all the 
clinical examination and investigations were done 
and patients were subjected to intervention after 
Poorvakarma as follows: 
Table 1: Poorva karma 
Treatment Medicine Dose Time Duration 
Sadyasneha Plain ghritha 10gm 8 pm, given with hot gruel 1st day 
Virechana Avipathychoornam 20g with honey 6 am in empty stomach 2nd day 
Table 2: Schedule of interventions: 
Treatment Medicine Dose Time Duration 
Nasya Ksheerabala 101 Avarti taila 
Thalam with Rasna jambeeram 
Mukhabhyanga with Balathailam 
5ml in each 
Nostril 
8 am in morning 
Empty  stomach 
7 days 
Internal 
medicines 
Gandhakakalpa 3g  
Anupana-8 drops of 
honey, 13 drops of 
ghee, 20 ml milk  
one and half 
hours after 
taking food at 
night 
After Nasya, for 
2 months. 
Pratimarsa 
nasya 
Ksheerabala 
101 AvartiTaila 
1ml in each nostril 4 pm 2 months 
(concurrent with 
Gandhakakalpa) 
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Outcome variable 
1. Change in The Daily Living Tasks Dependent on Vision questionnaire (DLTV) score. 
The DLTV consists of a core of 22 individual items each with a four point ordinal response scale.[6] 
2. Change in visual acuity assessed by LogMar Visual acuity chart by noting the change in visual acuity 
3. Change in Amsler grid findings: 
Assessed using a grading scale.[7] 
Grade 0: No distorted vision  
Grade 1: Lines are crooked or bent 
Grade 2: Boxes appeared different in size and shape from each other 
Grade 3: Boxes and lines are wavy, missing. 
Changes in OCT in the selected subset: 
OCT was taken on Zeiss Cirrhus HD OCT in a subset of 17 eyes.  
Retinal thickness in µm above an area with significant drusen was measured.[8-9] 
Statistical analysis 
Paired T test, Wilcoxon signed Rank test, Freidman’s test and McNemar test according to the type of 
distribution of the variable. 
RESULTS 
Majority of the patients had Vata- Pitta Prakruti, disturbed sleep, Avara Vyayamasakti, Avara Satva and 
Krurakoshta. Also Katu Amla Lavana Ahara, irregular food habits, Mandagni and Heena Abhyavaharana Sakti 
was found in a large proportion of patients. 
Because there were four outcome variables, the p value was adjusted by using Bonferroni’s correction method 
and therefore significance will be on the basis of p value less than 0.0125. 
Analysis of DLTV scores 
Table 3: Change in visual acuity according to no. of letters read in Log Mar Chart 
Change in visual acuity Frequency Percentage 
 BT-AT AT to AF BT-AF BT-AT AT-AF BT-AF 
Decreased 0 5 0 0 20.8 0 
Unchanged 10 16 11 41.6 66.6 45.8 
Improved by 1 letter 0 0 0 0 0 0 
Improved by 2 letter 3 0 2 12.5 0 8.3 
Improved by 3 letter 2 2 2 8.3 8.3 8.3 
Improved by 4 letter 0 0 1 0 0 4.2 
Improved by 5 letter 4 1 4 16.6 4.2 16.6 
Improved by 6 letter 0 0 1 0 0 4.2 
Improved by 7 letter 1 0 0 4.2 0 0 
Improved by 8 letter 2 0 2 8.3 0 8.3 
Improved by 9 letter 1 0 0 4.2 0 0 
Improved by 10 letter 1 0 1 4.2 0 4.2 
58.4% patients showed improvement in their visual acuity in the period between before treatment and after 
treatment. Visual acuity of 42% patients remained unchanged. 
Table 4: Log MAR visual acuity analysis 
Parameter  N visual acuity in Log MAR Paired 
comparison 
Paired difference Paired t test 
Mean SD Mean SD t p 
BT 24 0.470 0.174 BT vsAT 0.062 0.067 4.494 <0.001 
AT 24 0.532 0.182 BT vsAF 0.056 0.062 4.422 <0.001 
AF 24 0.526 0.179 AT vsAF 0.006 0.047 0.613 0.546 
(BT- before commencement of treatment, AT- after treatment, AF- At followup) 
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Graph No: 1 -Analysis of Log MAR visual acuity 
 
As the p values are less than 0.001, change in visual acuity scores of patients in the period before treatment and 
at follow up are very significant. 
Analysis of DLTV score 
Table 5: Analysis of DLTV scores in different points of time 
DLTV BT AT AF Test applied- Friedman’s test P value 
Mean 72.286 77.071 78.071  
 
 
χ 2 = 23.680 
 
 
 
0.0001 
Median 71.000 76.500 79.000 
SD 6.2071 6.2322 5.6496 
IQR 8 9.75 9.75 
(BT- before commencement of treatment, AT- after treatment, AF- At follow up) 
Graph 2: Analysis of DLTV scores 
 
As p value obtained is 0.0001, there are highly significant differences in the DLTV scores measured at the three 
time points, BT, AT and AF. The change in DLTV scores of patients in the period before treatment and at follow 
up is very significant.  
Analysis of Amsler grid findings 
Table 6: Analysis of Amsler grid finding 
Amsler grid BT AT AF 
N % N % N % 
Grade 0 19 79.2 21 87.5 21 87.5 
Grade 1 5 20.8 3 12.5 3 12.5 
Total 24 100.0 24 100.0 24 100.0 
Comparison with BT p  0.500 0.500 
(BT-before commencement of treatment, AT-after treatment, AF-at follow up)  
0: No distorted vision, Grade 1: Lines are crooked or bent) McNemar test p= 0.500 
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Graph no: 3- Analysis of Amsler grid findings 
 
Before treatment 79.2% patients had grade 0 findings in Amsler grid while 20.8% patients had grade 1 
findings. After treatment and at follow up only 12.5% patients had grade 1 findings. As p value is 0.500, the 
change in Amsler grid findings of patients before treatment and at follow up is not significant. 
Analysis of OCT findings 
Table 7: Analysis of OCT findings 
  
N 
OCT Paired 
comparison 
Paired difference Paired t test 
Mean SD Mean SD t P 
BT 9 222.0 29.0 BT vsAF 1.222 9.909 0.370 0.721 
AF 9 223.2 26.1 
Out of 17 eyes, 12 eyes had significant OCT findings of dry AMD. As 3 eyes dropped out, for statistical analysis 
only 9 eyes were considered. 
Graph no: 4- Analysis OCT findings 
 
The mean retinal thickness measured above drusen before treatment was 222±29 µm and that measured at 
follow up was 223±26µm. The p value obtained in paired T test was 0.721. So this is not statistically significant. 
DISCUSSION
 Dry age-related macular degeneration is a 
chronic progressive neurodegenerative disorder. The 
main mechanisms of its pathogenesis include genetic 
background, oxidative stress, chronic inflammation, 
lifestyle and diet. By analyzing Samprapti of the 
disease, dry AMD has a Vata- pitta predominance 
with associated Raktavahasrotodushti, and affects 
individuals in old age. Amongst the study patients, 
most had Vata-Pitta Prakruti. Here the Prakruti and 
disease are both Vata-pittadhika. It is possible that 
Vata-pittaprakruti individual may have a 
predisposition to develop dry AMD. Other patient 
related data like Katu, Amlalavana predominant diet, 
Heena Abhyavaharanasakti, Mandagni and irregular 
food habits seems to be dietary implications causing 
aggravation of Vata. Disturbed sleep, Avara 
Vyayamasakti, Avarasatva and Krurakoshta points to 
a predominant Vatakopa in the body. The effect of 
intervention on visual acuity and DLTV score of 
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patients was linear into the follow up period while it 
was negligible for OCT findings and Amsler grid. 
Probable mode of action of intervention 
  It can be inferred that the mode of drug 
action is a conglomerate effort of Dosha and 
Vyadhiharakarmas of chosen formulations and their 
individual components, action of Nasya karma and 
the order of application of interventions. 
A comprehensive review of individual drugs of 
Gandhakakalpa, reference of which is found in RRS 
Uparasadhaya, reveals that all the drugs have 
Rasayana and Chakshushya properties.[10-13] The 
Prabhava of the Yoga is imparting sharp vision equal 
to that of a vulture. In addition, Gandhaka is Deepana, 
Madhura and Atirasayana. Bhringaraja has Amahara 
karma.[14] Studies show that Triphala could be a 
potential source of natural antioxidants in preventing 
or slowing the progression of age-associated oxidative 
stress-related degenerative diseases.[15] Eclipta alba 
extract also has potent antioxidant properties and 
protect against neuronal damage induced by oxidative 
stress.[16] All these properties show that the drugs are 
Dosha and Vyadhipratyaneeka, and able to arrest the 
etiopathological factors. The Bhavana of Gandhaka in 
Bhirngaraja may also reduce the particle size of the 
compound thus enabling faster absorption of the drug 
with greater bioavailability. Madhu, Ghritha and milk 
as Anupana helps to assimilate the combination and 
provide a suitable vehicle for its drug action. Also 
having Ghritha as Anupana may make the lipid soluble 
components of the drug be able to cross the blood 
brain barrier. Drug absorption by transmembrane 
fusion across BBB is favoured by low molecular 
weight and lipid solubility.[17] 
Ksheerabala 101 Avarti Taila, mentioned in 
Vatasonitha chikitsa, Ashtangahridaya is apt for Vata-
Pittanubandha Raktadushti as it is Vata-Pitta Samana. 
It is Rasayana, Brimhana, Jeevaneeya and 
Indriyaprasadana. All these qualities are Vyadhi and 
Doshapratyaneeka and highly relevant to the 
treatment principles of dry AMD. Its individual 
components, Sida rhombifolia and sesame oil have 
high potential of antioxidant activity and free radical 
scavenging properties.[18-19] Milk is a rich source of 
various nutrients. Goksheera is Jeevaneeya, 
Brimhaneeya, Chakshushya and Vata-pitta hara.[20] 
Additionally, previous studies have shown 
Ksheerabala to be a neuroprotective agent in diseases 
induced by oxidative stress.[21] 
 The drug instilled in the nose is said to act 
by reaching Sringataka and then pervading to eye 
and nourishing the tissues. Nasal route drug 
delivery is an attractive strategy for brain targeted 
drug delivery as it allows therapeutic agents to be 
delivered to the brain via neural pathways such as 
the olfactory and trigeminal nerves, thereby 
bypassing the blood-brain barrier.[22] As the drug 
used for Nasya here is lipid based, absorption can 
occur through transcellular route as well.[23] 
Anatomically retina is an extension of CNS. Hence 
Nasya helps to deliver the Brimhana, Rasayana, 
Jeevaneeya and Indriyaprasadana properties of 
Ksheerabala 101 Avarti Taila to the targeted retina. 
The patients underwent Nasya after Virechana and 
Gandhaka Kalpa was administered after both 
Kayashudhi and Urdhwanga Shudhi. This makes the 
target tissues to be receptive to the Rasayana Gunas 
of the drug. 
CONCLUSION 
Nasya with Ksheerabala 101 Avarti Taila and 
internal administration of Gandhaka Kalpa is an 
effective intervention in the management of dry AMD 
along the lines of Ayurveda. The intervention was 
safe to use, and economical. A larger sample size 
would improve the accuracy. Since dry AMD has slow 
progression, yearly follow up and monitoring with 
regular measurement of the outcome variables will 
provide details on the nature of progression of 
disease in patients who received the intervention. 
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